GT Biopharma, Inc. (GTBP) Form 424B3 — Oct 20, 2026
GT Biopharma filed a 424B3 prospectus registering up to 13,502,835 shares for resale by selling stockholders from its September 2026 (Series M) and May 2025 (Series L) private placements, including conversion shares and warrant shares. The company receives no proceeds from these sales, though it may receive cash if warrants are exercised or greenshoe rights are purchased. The registered shares dwarf the current share count: 13.5 million shares versus only 2,061,052 shares outstanding, implying potential dilution of over 650% if fully converted and sold.
Key figures
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 13502835
- Shares Outstanding
- 2061052
- Reverse split ratio
- 1-for-25
- Closing price oct8 2026
- 5.96
- Preferred dividend rate
- 10% rising to 12% per annum
- Closing price oct19 2026
- 6.69
- Series l conversion price
- 11.35
- Series m conversion price
- 6.1
- Outstanding warrant shares
- 9393734
- Pre split shares outstanding
- 45109497
- Post split shares outstanding
- 1804379
- May 2025 placement stated value
- 6611111
- Series l warrant exercise price
- 11.35
- Series m dividend declared cash
- 38468
- Series m warrant exercise price
- 6.1
- May 2025 placement gross proceeds
- 5950000
- Series l greenshoe proceeds to date
- 9706500
- Series m greenshoe max stated value
- 34675615
- Weighted avg warrant exercise price
- 8.34
- September 2026 placement stated value
- 8611111
- September 2026 placement gross proceeds
- 7750000
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.